Role of haptoglobinin polycystic ovary syndrome (PCOS), obesity and disorders of glucose tolerance in premenopausal women

PLoS ONE

Volumn 4, Issue 5, 2009, Pages

  Álvarez Blasco, Francisco ^a,b   Martínez García, Ma Ángeles ^a,b   Luque Ramírez, Manuel ^a,b   Parraza, Naiara ^a   San Millán, José L ^a,b   Escobar Morreale, Héctor F ^a,b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HAPTOGLOBIN;

ADULT; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PREMENOPAUSE; PROTEIN BLOOD LEVEL; ADOLESCENT; BLOOD; GLUCOSE INTOLERANCE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADOLESCENT; ADULT; FEMALE; GENOTYPE; GLUCOSE INTOLERANCE; HAPTOGLOBINS; HUMANS; OBESITY; POLYCYSTIC OVARY SYNDROME; PREMENOPAUSE; YOUNG ADULT;

EID: 66049155363     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005606     Document Type: Article

References (36)

1. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, et al. (2006) Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91: 4237-4245.
2. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, et al. (2008) The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril: Oct 22.
3. Escobar-Morreale HF, Roldan B, Barrio R, Alonso M, Sancho J, et al. (2000) High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 85: 4182-4187.
4. Codner E, Escobar-Morreale HF (2007) Hyperandrogenism and polycystic ovary syndrome (PCOS) in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 92: 1209-1206.
5. Conn JJ, Jacobs HS, Conway GS (2000) The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol (Oxf) 52: 81-86.
6. Alvarez-Blasco F, Botella-Carretero JI, San Millan JL, Escobar-Morreale HF (2006) Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 166: 2081-2086.
7. Escobar-Morreale HF, Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, Sancho J, et al. (2005) Body iron stores are increased in overweight and obese women with polycystic ovary syndrome. Diabetes Care 28: 2042-2044.
8. Escobar-Morreale HF, Luque-Ramirez M, San Millan JL (2005) The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 26: 251-282.
9. Sabuncu T, Vural H, Harma M (2001) Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clinical Biochemistry 34: 407-413.
10. Legro RS (2003) Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 24: 302-312.
11. Botella-Carretero JI, Luque-Ramirez M, Alvarez-Blasco F, San Millan JL, Escobar-Morreale HF (2006) Mutations in the hereditary hemochromatosis gene are not associated with the increased body iron stores observed in overweight and obese women with polycystic ovary syndrome. Diabetes Care 29: 2556.
12. Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, Sanchon R, San Millan JL, et al. (2007) The increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism, and do not result from reduced menstrual losses. Diabetes Care 30: 2309-2313.
13. Fernandez-Real JM, Lopez-Bermejo A, Ricart W (2002) Cross-talk between iron metabolism and diabetes. Diabetes 51: 2348-2354.
14. Langlois MR, Delanghe JR (1996) Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 42: 1589-1600.
15. Bowman B (1993) Haptoglobin. In: Bowman BH, ed. Hepatic plasma proteins. San Diego: Academic Press. pp 159-167.
16. Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, et al. (2003) Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res 92: 1193-1200.
17. Langlois M, Martin M, Boelaert J, Beaumont C, Taes Y, et al. (2000) The haptoglobin 2-2 phenotype affects serum markers of iron status in healthy males. Clin Chem 46: 1619-1625.
18. Chiellini C, Santini F, Marsili A, Berti P, Bertacca A, et al. (2004) Serum haptoglobin: a novel marker of adiposity in humans. J Clin Endocrinol Metab 89: 2678-2683.
19. Matharoo-Ball B, Hughes C, Lancashire L, Tooth D, Ball G, et al. (2007) Characterization of biomarkers in polycystic ovary syndrome (PCOS) using multiple distinct proteomic platforms. J Proteome Res 6: 3321-3328.
20. Insenser M, Luque-Ramirez M, del Campo S, Moraleda G, Escobar-Morreale HF, et al. Differential expresion of plasma proteins in women with polycystic ovary syndrome; 2008 15-18 June 2008; San Francisco, CA.
21. Zawadzki JK, Dunaif A (1992) Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic ovary syndrome. Boston: Blackwell Scientific Publications. pp 377-384.
22. Flegal KM, Graubard BI, Williamson DF, Gail MH (2005) Excess deaths associated with underweight, overweight, and obesity. JAMA 293: 1861-1867.
23. Vermeulen A, Verdonck L, Kaufman JM (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84: 3666-3672.
24. Dati F, Schumann G, Thomas L, Aguzzi F, Baudner S, et al. (1996) Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP reference material (CRM 470). Eur J Clin Chem Clin Biochem 34: 517-520.
25. Koch W, Latz W, Eichinger M, Roguin A, Levy AP, et al. (2002) Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clin Chem 48: 1377-1382.
26. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470.
27. American Diabetes Association (2008) Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 31: S55-60.
28. Kelly CCJ, Lyall H, Petrie JR, Gould GW, Connell JMC, et al. (2001) Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86: 2453-2455.
29. Levy AP, Roguin A, Hochberg I, Herer P, Marsh S, et al. (2000) Haptoglobin phenotype and vascular complications in patients with diabetes. N Engl J Med 343: 969-970.
30. Levy A, Levy J, Kalet-Litman S, Miller-Lotan R, Levy N, et al. (2007) Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol 27: 134-140.
31. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF 2nd, et al. (2003) Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88: 2562-2568.
32. Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF (2007) Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome (PCOS). Hum Reprod 22: 3197-3203.
33. De Pergola G, Di Roma P, Paoli G, Guida P, Pannacciulli N, et al. (2007) Haptoglobin serum levels are independently associated with insulinemia in overweight and obese women. J Endocrinol Invest 30: 399-403.
34. Moirand R, Adams PC, Bicheler V, Brissot P, Deugnier Y (1997) Clinical features of genetic hemochromatosis in women compared with men. Ann Intern Med 127: 105-110.
35. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Sancho J, San Millan JL (2003) Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 46: 625-633.
36. Delanghe J, Langlois M, De Bacquer D, Mak R, Capel P, et al. (2002) Discriminative value of serum amyloid A and acute-phase proteins for coronary heart disease. Atherosclerosis 160: 471-476.